Abstract
Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion. Normal TP53 status is also its molecular feature. We report a case of oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation at recurrence after temozolomide therapy. The primary and recurrent tumors shared IDH1 and TERT promoter mutations. Although 1p/19q was codeleted in the primary tumor, it was imbalanced in the recurrent tumor harboring TP53 mutation. The copy-neutral loss of heterozygosity might have imbalanced the 1p/19q codeletion, while temozolomide therapy possibly caused the TP53 mutation. Such phenomena, although rare, should be noted during the clinical treatment of oligodendrogliomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H et al (2017) Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Commun 5:18. https://doi.org/10.1186/s40478-017-0422-z
Appin CL, Brat DJ (2015) Biomarker-driven diagnosis of diffuse gliomas. Mol Asp Med 45:87–96. https://doi.org/10.1016/j.mam.2015.05.002
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:112–120. https://doi.org/10.1038/s41586-019-1775-1
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121
Campbell BA, Horsman DE, Maguire J, Young S, Curman D, Ma R et al (2008) Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? J Neuro-Oncol 89:37–45. https://doi.org/10.1007/s11060-008-9597-2
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000
Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF (2018) Temozolomide-associated hypermutation in gliomas. Neuro-oncology 20:1300–1309. https://doi.org/10.1093/neuonc/noy016
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279
Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A (2013) Gliosarcoma arising from an oligodendroglioma (oligosarcoma). Clin Neuropathol 32:165–170. https://doi.org/10.5414/np300577
Kanamori M, Kumabe T, Shibahara I, Saito R, Yamashita Y, Sonoda Y et al (2013) Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases. Brain Tumor Pathol 30:151–159. https://doi.org/10.1007/s10014-012-0119-8
Louis DOH, Wiestler OD, Cavenee WK (eds) (2016) World Health Organization classification of tumours of the Central Nervous System Revised 4th Edition. Lyon, International Agency for Research on Cancer
Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135:639–642. https://doi.org/10.1007/s00401-018-1826-y
Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF et al (2012) Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-oncology 14:761–767. https://doi.org/10.1093/neuonc/nos065
Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. https://doi.org/10.1007/s00401-014-1370-3
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet (London, England) 379:1984–1996. https://doi.org/10.1016/s0140-6736(11)61346-9
Shoji T, Saito R, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2016) Sarcoma-like tumor originating from oligodendroglioma. Brain Tumor Pathol 33:255–260. https://doi.org/10.1007/s10014-016-0268-2
Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468. https://doi.org/10.1038/ng.3273
Vajtai I, Vassella E, Hewer E, Kappeler A, Reinert MM (2012) Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors. Pathol Res Pract 208:750–755. https://doi.org/10.1016/j.prp.2012.09.009
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880. https://doi.org/10.1200/jco.2009.23.6497
Acknowledgments
We thank Dr. Susumu Fushimi, Dr. Kenichi Shibata, Dr. Rui Kondo, and Dr. Satsuki Takahashi at the Hiraka General Hospital for providing clinical data and samples of the primary case. We also thank Dr. Akira Kurose at the Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine for his practical advice.
Molecular diagnoses in this study were funded by a grant from the Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant Number JP19K16823; Dr. Takahiro Ono received this grant.
Previous presentation
This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal.
Funding
Molecular diagnoses in this study were funded by a grant from the Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant Number JP19K16823; Dr. Takahiro Ono received this grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
The study design was approved by the appropriate ethics review board.
Consent to participate
Written informed consent was obtained from the participant in the study.
Consent to publish
The participant has consented to the submission of the case report to the journal.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Tumor - Glioma
Rights and permissions
About this article
Cite this article
Ono, T., Reinhardt, A., Takahashi, M. et al. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. Acta Neurochir 162, 3019–3024 (2020). https://doi.org/10.1007/s00701-020-04514-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00701-020-04514-3